clinmedКлиническая медицинаClinical Medicine (Russian Journal)0023-21492412-1339ООО «Медицинское информационное агентство»10.30629/0023-2149-2023-101-9-10-454-466clinmed-629Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESНаночастицы для адресной доставки лекарственных средств в современной кардиологииNanoparticles for targeted drug delivery in modern cardiologyhttps://orcid.org/0009-0001-3550-9689КиденкоВ. А.KidenkoV. A.

Киденко Виктория Александровна — канд. мед. наук, ассистент кафедры внутренних болезней № 3

344022, Ростов-на-Дону

Kidenko Victoria A.

344022, Rostov-on-Don

sagidullin12@bk.ruhttps://orcid.org/0009-0007-6333-4699МетоваМ. М.MetovaM. M.

Метова Мариетта Муратовна — ординатор кафедры внутренних болезней № 3

344022, Ростов-на-Дону

Metova Marietta M.

344022, Rostov-on-Don

https://orcid.org/0000-0002-0650-2461ГабриелянЕ. Ю.GabrielyanE. Yu.

Габриелян Елизавета Юрьевна — ординатор кафедры кардиологии, ревматологии и функциональной диагностики

344022, Ростов-на-Дону

Gabrielyan Elizaveta Yu.

344022, Rostov-on-Don

https://orcid.org/0000-0001-6407-3880ТрусовЮ. А.TrusovYu. A.

Трусов Юрий Александрович — врач-кардиолог, ассистент

443099, Самара

Trusov Yuri A.

443099, Samara

https://orcid.org/0009-0008-8743-6478МелиховаА. Д.MelikhovaA. D.

Мелихова Анастасия Дмитриевна — аспирант кафедры внутренних болезней № 3

344022, Ростов-на-Дону

Melikhova Anastatiya D.

344022, Rostov-on-Don

https://orcid.org/0009-0003-8777-3259МуслимоваЕ. П.MuslimovaE. P.

Муслимова Елена Павловна — ординатор

Уфа

Muslimova Elena P.

450008, Ufa

https://orcid.org/0009-0007-0405-4849СедьмоваЯ. В.SedmovaYa. V.

Седьмова Яна Вячеславовна — студентка 6-го курса

443099, Самара

Sedmova Yana V.

443099, Samara

https://orcid.org/0009-0005-4696-4192ХабибуллинаК. Р.KhabibullinaK. R.

Хабибуллина Камила Рустемовна — аспирант кафедры госпитальной терапии №1

Уфа

Khabibullina Kamilla R.

450008, Ufa

https://orcid.org/0009-0005-5051-2615МаликоваЕ. В.MalikovaE. V.

Маликова Елизавета Владимировна — ординатор кафедры кардиологии, ревматологии и функциональной диагностики

344022, Ростов-на-Дону

Mаlikova Elizaveta V.

344022, Rostov-on-Don

https://orcid.org/0000-0001-5893-7881ВалиуллинаЛ. А.ValiullinaL. A.

Валиуллина Лилия Альбертовна — студентка

Уфа

Valiullina Lilia A.

450008, Ufa

https://orcid.org/0000-0001-6834-6073БагаутдиноваД. Д.BagautdinovaD. D.

Багаутдинова Диана Дамировна — студентка 6-го курса

Уфа

Bagautdinova Diana D.

450008, Ufa

ПетраковаА. В.PetrakovaA. V.

Петракова Анна Вадимовна — аспирант

344022, Ростов-на-Дону

Petrakova Anna V.

344022, Rostov-on-Don

https://orcid.org/0009-0004-7664-6163ТерехинаК. С.TerekhinaK. S.

Терехина Ксения Сергеевна — доцент кафедры госпитальной терапии №2

Уфа

Terekhina Ksenia S.

450008, Ufa

ФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава РоссииРоссияRostov State Medical University of the Ministry of Health of RussiaRussian FederationФГБОУ ВО «Самарский государственный медицинский университет» Минздрава РоссииРоссияSamara State Medical University of the Ministry of Health of RussiaRussian FederationФГБОУ ВО «Башкирский государственный медицинский университетРоссияBashkir State Medical University of the Ministry of Health of RussiaRussian Federation2023121120231019-10454466Copyright © Киденко В.А., Метова М.М., Габриелян Е.Ю., Трусов Ю.А., Мелихова А.Д., Муслимова Е.П., Седьмова Я.В., Хабибуллина К.Р., Маликова Е.В., Валиуллина Л.А., Багаутдинова Д.Д., Петракова А.В., Терехина К.С., 20232023Киденко В.А., Метова М.М., Габриелян Е.Ю., Трусов Ю.А., Мелихова А.Д., Муслимова Е.П., Седьмова Я.В., Хабибуллина К.Р., Маликова Е.В., Валиуллина Л.А., Багаутдинова Д.Д., Петракова А.В., Терехина К.С.Kidenko V.A., Metova M.M., Gabrielyan E.Y., Trusov Y.A., Melikhova A.D., Muslimova E.P., Sedmova Y.V., Khabibullina K.R., Malikova E.V., Valiullina L.A., Bagautdinova D.D., Petrakova A.V., Terekhina K.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinmedjournal.com/jour/article/view/629

Инфаркт миокарда (ИМ) является ведущей причиной смерти во всем мире. Потеря кардиомиоцитов в результате повреждений, таких как ИМ, часто приводит к фиброзному рубцеванию и угнетению сердечной функции. Использование систем адресной доставки лекарств всегда необходимо, поскольку они обеспечивают уникальные преимущества для повышения эффективности и снижения нежелательных эффектов. Наночастицы (НЧ) являются наиболее распространенными средствами доставки терапевтических агентов к ткани-мишени. НЧ для доставки лекарственных средств могут состоять из различных наноматериалов и структур, включая липиды, полимеры, дендримеры, углеродные нанотрубки и металлические наночастицы. Нами были рассмотрены подходы к кардиоспецифической доставке терапевтических средств на основе НЧ для лечения ишемической болезни сердца в доклинических и клинических исследованиях. Доставка лекарственных веществ на основе НЧ обладает потенциалом для специфического нацеливания на ткани и клетки, а также для пролонгированного высвобождения множества терапевтических агентов. Однако применение НЧ в терапии сердечно-сосудистых заболеваний относительно ограниченно по сравнению с другими областями, такими как онкология и неврология. Одним из основных препятствий является отсутствие специфичности в современных системах нацеливания на сердце. Будущие исследования необходимы для выявления специфических лигандов/рецепторов в кардиомиоцитах и разработки новых НЧ с высокой аффинностью и специфичностью.

Myocardial infarction (MI) is the leading cause of death worldwide. The loss of cardiomyocytes resulting from injuries such as acute MI often leads to fibrotic scarring and depressed cardiac function. The use of targeted drug delivery systems is always necessary as they provide unique advantages for increasing efficacy and reducing undesirable effects. Nanoparticles (NPs) are the most common means of delivering therapeutic agents to target tissues. NPs for drug delivery can be composed of various nanomaterials and structures, including lipids, polymers, dendrimers, carbon nanotubes, and metal nanoparticles. We have reviewed approaches to cardio-specific drug delivery based on NPs for the treatment of ischemic heart disease in preclinical and clinical studies. Drug delivery based on NPs has the potential for specific targeting of tissues and cells, as well as for prolonged release of multiple therapeutic agents. However, the use of NPs in the therapy of cardiovascular diseases is relatively limited compared to other areas such as oncology and neurology. One of the main obstacles is the lack of specificity in current targeting systems for the heart. Future research is needed to identify specific ligands/receptors in cardiomyocytes and develop new NPs with high affinity and specificity.

наночастицыадресная доставкакардиологиямолекулярная биологияинфаркт миокардаишемическая болезнь сердцаnanoparticlestargeted deliverycardiologymolecular biologymyocardial infarctionischemic heart diseaseReferencesLi J., Hu S., Zhu D., Huang K., Mei X., López de Juan Abad B., Cheng K. All roads lead to rome (the heart): cell retention and outcomes from various delivery routes of cell therapy products to the heart. J. Am. Heart Assoc. 2021;10(8):e020402. DOI: 10.1161/JAHA.120.020402Li J., Hu S., Zhu D., Huang K., Mei X., López de Juan Abad B., Cheng K. All roads lead to rome (the heart): cell retention and outcomes from various delivery routes of cell therapy products to the heart. J. Am. Heart Assoc. 2021;10(8):e020402. DOI: 10.1161/JAHA.120.020402Sahoo S., Kariya T., Ishikawa K. Targeted delivery of therapeutic agents to the heart. Nat Rev. Cardiol. 2021;18(6):389–399. DOI: 10.1038/s41569–020–00499–9Sahoo S., Kariya T., Ishikawa K. Targeted delivery of therapeutic agents to the heart. Nat Rev. Cardiol. 2021;18(6):389–399. DOI: 10.1038/s41569–020–00499–9Razavi E., Ramezani A., Kazemi A., Attar A. Effect of treatment with colchicine after acute coronary syndrome on major cardiovascular events: a systematic review and meta-analysis of clinical trials. Cardiovasc. Ther. 2022; 2022:8317011. DOI: 10.1155/2022/8317011Razavi E., Ramezani A., Kazemi A., Attar A. Effect of treatment with colchicine after acute coronary syndrome on major cardiovascular events: a systematic review and meta-analysis of clinical trials. Cardiovasc. Ther. 2022; 2022:8317011. DOI: 10.1155/2022/8317011Wang D., Liu B., Xiong T., Yu W., Yang H., Wang J., Jing X., She Q. Transcription factor Foxp1 stimulates angiogenesis in adult rats after myocardial infarction. Cell Death. Discov. 2022;10;8(1):381. DOI: 10.1038/s41420–022–01180–5Wang D., Liu B., Xiong T., Yu W., Yang H., Wang J., Jing X., She Q. Transcription factor Foxp1 stimulates angiogenesis in adult rats after myocardial infarction. Cell Death. Discov. 2022;10;8(1):381. DOI: 10.1038/s41420–022–01180–5Monahan D.S., Almas T., Wyile R., Cheema F.H., Duffy G.P., Hameed A. Towards the use of localised delivery strategies to counteract cancer therapy-induced cardiotoxicities. Drug. Deliv. Transl. Res. 2021;11(5):1924–1942. DOI: 10.1007/s13346–020–00885–3Monahan D.S., Almas T., Wyile R., Cheema F.H., Duffy G.P., Hameed A. Towards the use of localised delivery strategies to counteract cancer therapy-induced cardiotoxicities. Drug. Deliv. Transl. Res. 2021;11(5):1924–1942. DOI: 10.1007/s13346–020–00885–3Monahan D.S., Flaherty E., Hameed A., Duffy G.P. Resveratrol signifi cantly improves cell survival in comparison to dexrazoxane and carvedilol in a h9c2 model of doxorubicin induced cardiotoxicity. Biomed. Pharmacother. 2021;140:111702. DOI: 10.1016/j.biopha.2021.111702Monahan D.S., Flaherty E., Hameed A., Duffy G.P. Resveratrol signifi cantly improves cell survival in comparison to dexrazoxane and carvedilol in a h9c2 model of doxorubicin induced cardiotoxicity. Biomed. Pharmacother. 2021;140:111702. DOI: 10.1016/j.biopha.2021.111702Gastl M., Sürder D., Corti R., Faruque Osmany D.M.M., Gotschy A., von Spizcak J., Sokolska J., Metzen D., Alkadhi H., Ruschitzka F., Kozerke S., Manka R. Effect of intracoronary bone marrow-derived mononuclear cell injection early and late after myocardial infarction on CMR-derived myocardial strain. Int. J. Cardiol. 2020;310:108– 115. DOI: 10.1016/j.ijcard.2020.01.025Gastl M., Sürder D., Corti R., Faruque Osmany D.M.M., Gotschy A., von Spizcak J., Sokolska J., Metzen D., Alkadhi H., Ruschitzka F., Kozerke S., Manka R. Effect of intracoronary bone marrow-derived mononuclear cell injection early and late after myocardial infarction on CMR-derived myocardial strain. Int. J. Cardiol. 2020;310:108– 115. DOI: 10.1016/j.ijcard.2020.01.025Lamirault G., de Bock E., Sébille V., Delasalle B., Roncalli J., Susen S., Piot C., Trochu J.N., Teiger E., Neuder Y., Le Tourneau T., Manrique A., Hardouin J.B., Lemarchand P. Sustained quality of life improvement after intracoronary injection of autologous bone marrow cells in the setting of acute myocardial infarction: results from the BONAMI trial. Qual. Life Res. 2017;26(1):121–125. DOI: 10.1007/s11136–016–1366–7Lamirault G., de Bock E., Sébille V., Delasalle B., Roncalli J., Susen S., Piot C., Trochu J.N., Teiger E., Neuder Y., Le Tourneau T., Manrique A., Hardouin J.B., Lemarchand P. Sustained quality of life improvement after intracoronary injection of autologous bone marrow cells in the setting of acute myocardial infarction: results from the BONAMI trial. Qual. Life Res. 2017;26(1):121–125. DOI: 10.1007/s11136–016–1366–7Zhang J., Wu Z., Fan Z., Qin Z., Wang Y., Chen J., Wu M., Chen Y., Wu C., Wang J. Pericardial application as a new route for implanting stem-cell cardiospheres to treat myocardial infarction. J. Physiol. 2018;596(11):2037–2054. DOI: 10.1113/JP275548Zhang J., Wu Z., Fan Z., Qin Z., Wang Y., Chen J., Wu M., Chen Y., Wu C., Wang J. Pericardial application as a new route for implanting stem-cell cardiospheres to treat myocardial infarction. J. Physiol. 2018;596(11):2037–2054. DOI: 10.1113/JP275548Dergilev K.V., Tsokolayeva Z.I., Beloglazova I.B., Ratner E.I., Parfyonova E.V. Epicardial transplantation of cardiac progenitor cells based cells sheets is more promising method for stimulation of myocardial regeneration, than conventional cell injections. Kardiologiia. 2019;59(5):53–60. DOI: h10.18087/cardio.2019.5.2597Dergilev K.V., Tsokolayeva Z.I., Beloglazova I.B., Ratner E.I., Parfyonova E.V. Epicardial transplantation of cardiac progenitor cells based cells sheets is more promising method for stimulation of myocardial regeneration, than conventional cell injections. Kardiologiia. 2019;59(5):53–60. DOI: h10.18087/cardio.2019.5.2597Lin X., Liu Y., Bai A., Cai H., Bai Y., Jiang W., Yang H., Wang X., Yang L., Sun N., Gao H. A viscoelastic adhesive epicardial patch for treating myocardial infarction. Nat. Biomed. Eng. 2019;3(8):632– 643. DOI: 10.1038/s41551–019–0380–9Lin X., Liu Y., Bai A., Cai H., Bai Y., Jiang W., Yang H., Wang X., Yang L., Sun N., Gao H. A viscoelastic adhesive epicardial patch for treating myocardial infarction. Nat. Biomed. Eng. 2019;3(8):632– 643. DOI: 10.1038/s41551–019–0380–9Mathieu E., Lamirault G., Toquet C., Lhommet P., Rederstorff E., Sourice S., Biteau K., Hulin P., Forest V., Weiss P., Guicheux J., Lemarchand P. Intramyocardial delivery of mesenchymal stem cell-seeded hydrogel preserves cardiac function and attenuates ventricular remodeling after myocardial infarction. PLoS One. 2012;7(12):e51991. DOI: 10.1371/journal.pone.0051991Mathieu E., Lamirault G., Toquet C., Lhommet P., Rederstorff E., Sourice S., Biteau K., Hulin P., Forest V., Weiss P., Guicheux J., Lemarchand P. Intramyocardial delivery of mesenchymal stem cell-seeded hydrogel preserves cardiac function and attenuates ventricular remodeling after myocardial infarction. PLoS One. 2012;7(12):e51991. DOI: 10.1371/journal.pone.0051991Zeng X., Zou L., Levine R.A., Guerrero J.L., Handschumacher M.D., Sullivan S.M., Braithwaite G.J.C., Stone J.R., Solis J., Muratoglu O.K., Vlahakes G.J., Hung J. Effi cacy of polymer injection for ischemic mitral regurgitation: persistent reduction of mitral regurgitation and attenuation of left ventricular remodeling. JACC Cardiovasc. Interv. 2015;8(2):355–363. DOI: 10.1016/j.jcin.2014.09.016Zeng X., Zou L., Levine R.A., Guerrero J.L., Handschumacher M.D., Sullivan S.M., Braithwaite G.J.C., Stone J.R., Solis J., Muratoglu O.K., Vlahakes G.J., Hung J. Effi cacy of polymer injection for ischemic mitral regurgitation: persistent reduction of mitral regurgitation and attenuation of left ventricular remodeling. JACC Cardiovasc. Interv. 2015;8(2):355–363. DOI: 10.1016/j.jcin.2014.09.016Mihic A., Cui Z., Wu J., Vlacic G., Miyagi Y., Li S.H., Lu S., Sung H.W., Weisel R.D., Li R.K. A Conductive polymer hydrogel supports cell electrical signaling and improves cardiac function after implantation into myocardial infarct. Circulation. 2015;132(8):772– 84. DOI: 10.1161/CIRCULATIONAHA.114.014937Mihic A., Cui Z., Wu J., Vlacic G., Miyagi Y., Li S.H., Lu S., Sung H.W., Weisel R.D., Li R.K. A Conductive polymer hydrogel supports cell electrical signaling and improves cardiac function after implantation into myocardial infarct. Circulation. 2015;132(8):772– 84. DOI: 10.1161/CIRCULATIONAHA.114.014937Fan C., Joshi J., Li F., Xu B., Khan M., Yang J., Zhu W. Nanoparticle-mediated drug delivery for treatment of ischemic heart disease. Front. Bioeng. Biotechnol. 2020;8:687. DOI: 10.3389/fbioe.2020.00687Fan C., Joshi J., Li F., Xu B., Khan M., Yang J., Zhu W. Nanoparticle-mediated drug delivery for treatment of ischemic heart disease. Front. Bioeng. Biotechnol. 2020;8:687. DOI: 10.3389/fbioe.2020.00687Yang F., Xue J., Wang G., Diao Q. Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases. Front. Pharmacol. 2022; 13:999404. DOI: 10.3389/fphar.2022.999404Yang F., Xue J., Wang G., Diao Q. Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases. Front. Pharmacol. 2022; 13:999404. DOI: 10.3389/fphar.2022.999404Li C., Naveed M., Dar K., Liu Z., Baig M.M.F.A., Lv R., Saeed M., Dingding C., Feng Y., Xiaohui Z. Therapeutic advances in cardiac targeted drug delivery: from theory to practice. J. Drug. Target. 2021; 29(3):235–248. DOI: 10.1080/1061186X.2020.1818761Li C., Naveed M., Dar K., Liu Z., Baig M.M.F.A., Lv R., Saeed M., Dingding C., Feng Y., Xiaohui Z. Therapeutic advances in cardiac targeted drug delivery: from theory to practice. J. Drug. Target. 2021; 29(3):235–248. DOI: 10.1080/1061186X.2020.1818761Li Z., Hu S., Cheng K. Platelets and their biomimetics for regenerative medicine and cancer therapies. J. Mater. Chem B. 2018;6(45):7354– 7365. DOI: 10.1039/C8TB02301HLi Z., Hu S., Cheng K. Platelets and their biomimetics for regenerative medicine and cancer therapies. J. Mater. Chem B. 2018;6(45):7354– 7365. DOI: 10.1039/C8TB02301HSu T., Huang K., Ma H., Liang H., Dinh P.U., Chen J., Shen D., Allen T.A., Qiao L., Li Z., Hu S., Cores J., Frame B.N., Young A.T., Yin Q., Liu J., Qian L., Caranasos T.G., Brudno Y., Ligler F.S., Cheng K. Platelet-inspired nanocells for targeted heart repair after ischemia/reperfusion injury. Adv. Funct. Mater. 2019;29(4):1803567. DOI: 10.1002/adfm.201803567Su T., Huang K., Ma H., Liang H., Dinh P.U., Chen J., Shen D., Allen T.A., Qiao L., Li Z., Hu S., Cores J., Frame B.N., Young A.T., Yin Q., Liu J., Qian L., Caranasos T.G., Brudno Y., Ligler F.S., Cheng K. Platelet-inspired nanocells for targeted heart repair after ischemia/reperfusion injury. Adv. Funct. Mater. 2019;29(4):1803567. DOI: 10.1002/adfm.201803567Cannatà A., Ali H., Sinagra G., Giacca M. Gene therapy for the heart lessons learned and future perspectives. Circ. Res. 2020;126(10):1394– 1414. DOI: 10.1161/CIRCRESAHA.120.315855Cannatà A., Ali H., Sinagra G., Giacca M. Gene therapy for the heart lessons learned and future perspectives. Circ. Res. 2020;126(10):1394– 1414. DOI: 10.1161/CIRCRESAHA.120.315855O'Dwyer J., Murphy R., González-Vázquez A., Kovarova L., Pravda M., Velebny V., Heise A., Duffy G.P., Cryan S.A. Translational studies on the potential of a VEGF nanoparticle-loaded hyaluronic acid hydrogel. Pharmaceutics. 2021;13(6):779. DOI: 10.3390/pharmaceutics13060779O'Dwyer J., Murphy R., González-Vázquez A., Kovarova L., Pravda M., Velebny V., Heise A., Duffy G.P., Cryan S.A. Translational studies on the potential of a VEGF nanoparticle-loaded hyaluronic acid hydrogel. Pharmaceutics. 2021;13(6):779. DOI: 10.3390/pharmaceutics13060779Pala R., Pattnaik S., Busi S., Nauli S .M. Nanomaterials as Novel Cardiovascular theranostics. Pharmaceutics. 2021;13(3):348. DOI: 10.3390/pharmaceutics13030348Pala R., Pattnaik S., Busi S., Nauli S .M. Nanomaterials as Novel Cardiovascular theranostics. Pharmaceutics. 2021;13(3):348. DOI: 10.3390/pharmaceutics13030348Wang D.K., Rahimi M., Filgueira C.S. Nanotechnology applications for cardiovascular disease treatment: Current and future perspectives. Nanomedicine. 2021;34:102387. DOI: 10.1016/j.nano.2021.102387Wang D.K., Rahimi M., Filgueira C.S. Nanotechnology applications for cardiovascular disease treatment: Current and future perspectives. Nanomedicine. 2021;34:102387. DOI: 10.1016/j.nano.2021.102387Joshi J., Kothapalli C.R. Nanofi bers based tissue engineering and drug delivery approaches for myocardial regeneration. Curr. Pharm. Des. 2015;21(15):2006–20. DOI: 10.2174/1381612821666150302153138Joshi J., Kothapalli C.R. Nanofi bers based tissue engineering and drug delivery approaches for myocardial regeneration. Curr. Pharm. Des. 2015;21(15):2006–20. DOI: 10.2174/1381612821666150302153138Soares S., Sousa J., Pais A., Vitorino C. Nanomedicine: principles, properties and regulatory issues. Front. Chem. 2018;6:360. DOI https://doi.org/10.3389/fchem.2018.00360Soares S., Sousa J., Pais A., Vitorino C. Nanomedicine: principles, properties and regulatory issues. Front. Chem. 2018;6:360. DOI https://doi.org/10.3389/fchem.2018.00360Hoshyar N., Gray S., Han H., Bao G. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomedicine (Lond). 2016;11(6):673–92. DOI: 10.2217/nnm.16.5Hoshyar N., Gray S., Han H., Bao G. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomedicine (Lond). 2016;11(6):673–92. DOI: 10.2217/nnm.16.5Boltnarova B., Kubackova J., Skoda J., Stefela A., Smekalova M., Svacinova P., Pavkova I., Dittrich M., Scherman D., Zbytovska J., Pavek P., Holas O. PLGA Based Nanospheres as a Potent Macrophage-Specifi c Drug Delivery System. Nanomaterials (Basel). 2021;11(3):749. DOI: 10.3390/nano11030749Boltnarova B., Kubackova J., Skoda J., Stefela A., Smekalova M., Svacinova P., Pavkova I., Dittrich M., Scherman D., Zbytovska J., Pavek P., Holas O. PLGA Based Nanospheres as a Potent Macrophage-Specifi c Drug Delivery System. Nanomaterials (Basel). 2021;11(3):749. DOI: 10.3390/nano11030749Lloris-Garcerá P., Klinter S., Chen L., Skynner M.J., Löving R., Frauenfeld J. DirectMX — one-step reconstitution of membrane proteins from crude cell membranes into salipro nanoparticles. Front. Bioeng. Biotechnol. 2020;8:215. DOI: 10.3389/fbioe.2020.00215Lloris-Garcerá P., Klinter S., Chen L., Skynner M.J., Löving R., Frauenfeld J. DirectMX — one-step reconstitution of membrane proteins from crude cell membranes into salipro nanoparticles. Front. Bioeng. Biotechnol. 2020;8:215. DOI: 10.3389/fbioe.2020.00215Medina–Cruz D., Mostafavi E., Vernet-Crua A., Cheng J., Shah V., Cholula-Diaz J.L., Guisbiers G., Tao J., García-Martín J.M., Webster T.J. Green nanotechnology-based drug delivery systems for osteogenic disorders. Expert Opin. Drug. Deliv. 2020;17(3):341–356. DOI: 10.1080/17425247.2020.1727441Medina–Cruz D., Mostafavi E., Vernet-Crua A., Cheng J., Shah V., Cholula-Diaz J.L., Guisbiers G., Tao J., García-Martín J.M., Webster T.J. Green nanotechnology-based drug delivery systems for osteogenic disorders. Expert Opin. Drug. Deliv. 2020;17(3):341–356. DOI: 10.1080/17425247.2020.1727441Aziz A., Rehman U., Sheikh A., Abourehab M.A.S., Kesharwani P. Lipid–based nanocarrier mediated CRISPR/Cas9 delivery for cancer therapy. J. Biomater. Sci. Polym Ed. 2023;34(3):398–418. DOI: 10.1080/09205063.2022.2121592Aziz A., Rehman U., Sheikh A., Abourehab M.A.S., Kesharwani P. Lipid–based nanocarrier mediated CRISPR/Cas9 delivery for cancer therapy. J. Biomater. Sci. Polym Ed. 2023;34(3):398–418. DOI: 10.1080/09205063.2022.2121592Yu C.H., Betrehem U.M., Ali N., Khan A., Ali F., Nawaz S., Sajid M., Yang Y., Chen T., Bilal M. Design strategies., surface functionalization., and environmental remediation potentialities of polymer-functionalized nanocomposites. Chemosphere. 2022;306:135656. DOI: 10.1016/j.chemosphere.2022.135656Yu C.H., Betrehem U.M., Ali N., Khan A., Ali F., Nawaz S., Sajid M., Yang Y., Chen T., Bilal M. Design strategies., surface functionalization., and environmental remediation potentialities of polymer-functionalized nanocomposites. Chemosphere. 2022;306:135656. DOI: 10.1016/j.chemosphere.2022.135656Radhakrishnan D., Mohanan S., Choi G., Choy J.H., Tiburcius S., Trinh H.T., Bolan S., Verrills N., Tanwar P., Karakoti A., Vinu A. The emergence of nanoporous materials in lung cancer therapy. Sci. Technol. Adv. Mater. 2022;23(1):225–274. DOI: 10.1080/14686996.2022.2052181Radhakrishnan D., Mohanan S., Choi G., Choy J.H., Tiburcius S., Trinh H.T., Bolan S., Verrills N., Tanwar P., Karakoti A., Vinu A. The emergence of nanoporous materials in lung cancer therapy. Sci. Technol. Adv. Mater. 2022;23(1):225–274. DOI: 10.1080/14686996.2022.2052181Katsuki S., Matoba T., Koga J.I., Nakano K., Egashira K. Anti-in- flammatory nanomedicine for cardiovascular disease. Front. Cardiovasc. Med. 2017;4:87. DOI: 10.3389/fcvm.2017.00087Katsuki S., Matoba T., Koga J.I., Nakano K., Egashira K. Anti-in- flammatory nanomedicine for cardiovascular disease. Front. Cardiovasc. Med. 2017;4:87. DOI: 10.3389/fcvm.2017.00087Vinhas R., Mendes R., Fernandes A.R., Baptista P.V. Nanoparticles-Emerging Potential for Managing Leukemia and Lymphoma. Front. Bioeng Biotechnol. 2017;5:79. DOI: 10.3389/fbioe.2017.00079Vinhas R., Mendes R., Fernandes A.R., Baptista P.V. Nanoparticles-Emerging Potential for Managing Leukemia and Lymphoma. Front. Bioeng Biotechnol. 2017;5:79. DOI: 10.3389/fbioe.2017.00079Pascual-Gil S., Simón -Yarza T., Garbayo E., Prósper F., BlancoPrieto M.J. Cytokine -loaded PLGA and PEG-PLGA microparticles showed similar heart regeneration in a rat myocardial infarction model. Int. J. Pharm. 2017;523(2):531–533. DOI: 10.1016/j.ijpharm.2016.11.022Pascual-Gil S., Simón -Yarza T., Garbayo E., Prósper F., BlancoPrieto M.J. Cytokine -loaded PLGA and PEG-PLGA microparticles showed similar heart regeneration in a rat myocardial infarction model. Int. J. Pharm. 2017;523(2):531–533. DOI: 10.1016/j.ijpharm.2016.11.022Raphey V.R., Henna T.K., Nivitha K.P., Mufeedha P., Sabu C., Pramod K. Advanced biomedical applications of carbon nanotube. Mater Sci. Eng. C Mater Biol. Appl. 2019;100:616–630. DOI: 10.1016/j.msec.2019.03.043Raphey V.R., Henna T.K., Nivitha K.P., Mufeedha P., Sabu C., Pramod K. Advanced biomedical applications of carbon nanotube. Mater Sci. Eng. C Mater Biol. Appl. 2019;100:616–630. DOI: 10.1016/j.msec.2019.03.043Noon W.H., Kong Y., Ma J. Molecular dynamics analysis of a buckyball–antibody complex. Proc. Natl. Acad. Sci. U S A. 2002; 99(2):6466–70. DOI: 10.1073/pnas.022532599Noon W.H., Kong Y., Ma J. Molecular dynamics analysis of a buckyball–antibody complex. Proc. Natl. Acad. Sci. U S A. 2002; 99(2):6466–70. DOI: 10.1073/pnas.022532599Lai C., Lia L., Luoa B., Shena J., Shaoa J. Current advances and prospects in carbon nanomaterials-based drug delivery systems for cancer therapy. Curr. Med. Chem. 2022. DOI: 10.2174/0929867329666220821195353Lai C., Lia L., Luoa B., Shena J., Shaoa J. Current advances and prospects in carbon nanomaterials-based drug delivery systems for cancer therapy. Curr. Med. Chem. 2022. DOI: 10.2174/0929867329666220821195353Yañez-Aulestia A., Gupta N.K., Hernández M., Osorio-Toribio G., Sánchez-González E., Guzmán-Vargas A., Rivera J.L., Ibarra I.A., Lima E. Gold nanoparticles: current and upcoming biomedical applications in sensing, drug and gene delivery. Chem. Commun. (Camb). 2022;58(78):10886–10895. DOI: 10.1039/d2cc04826dYañez-Aulestia A., Gupta N.K., Hernández M., Osorio-Toribio G., Sánchez-González E., Guzmán-Vargas A., Rivera J.L., Ibarra I.A., Lima E. Gold nanoparticles: current and upcoming biomedical applications in sensing, drug and gene delivery. Chem. Commun. (Camb). 2022;58(78):10886–10895. DOI: 10.1039/d2cc04826dSakthi Devi R., Girigoswami A., Siddharth M., Girigoswami K. Applications of Gold and Silver Nanoparticles in Theranostics. Appl. Biochem. Biotechnol. 2022;194(9):4187–4219. DOI: 10.1007/s12010-022-03963-zSakthi Devi R., Girigoswami A., Siddharth M., Girigoswami K. Applications of Gold and Silver Nanoparticles in Theranostics. Appl. Biochem. Biotechnol. 2022;194(9):4187–4219. DOI: 10.1007/s12010-022-03963-zAhmad F., Salem-Bekhit M.M., Khan F., Alshehri S., Khan A., Ghoneim M.M., Wu H.F., Taha E.I., Elbagory I. Unique properties of surface-functionalized nanoparticles for bio-application: functionalization mechanisms and importance in application. Nanomaterials (Basel). 2022;12(8):1333. DOI: 10.3390/nano12081333Ahmad F., Salem-Bekhit M.M., Khan F., Alshehri S., Khan A., Ghoneim M.M., Wu H.F., Taha E.I., Elbagory I. Unique properties of surface-functionalized nanoparticles for bio-application: functionalization mechanisms and importance in application. Nanomaterials (Basel). 2022;12(8):1333. DOI: 10.3390/nano12081333Shepherd S.J., Issadore D., Mitchell M.J. Microfl uidic formulation of nanoparticles for biomedical applications. Biomaterials. 2021;274:120826. DOI: 10.1016/j.biomaterials.2021.120826Shepherd S.J., Issadore D., Mitchell M.J. Microfl uidic formulation of nanoparticles for biomedical applications. Biomaterials. 2021;274:120826. DOI: 10.1016/j.biomaterials.2021.120826Morgan M.T., Carnahan M.A., Finkelstein S., Prata C.A., Degoricija L., Lee S.J., Grinstaff M.W. Dendritic supramolecular assemblies for drug delivery. Chem. Commun. (Camb). 2005;(34):4309– 11. DOI: 10.1039/b502411kMorgan M.T., Carnahan M.A., Finkelstein S., Prata C.A., Degoricija L., Lee S.J., Grinstaff M.W. Dendritic supramolecular assemblies for drug delivery. Chem. Commun. (Camb). 2005;(34):4309– 11. DOI: 10.1039/b502411kNamdari M., Cheraghi M., Negahdari B., Eatemadi A., Daraee H. Recent advances in magnetoliposome for heart drug delivery. Artif. Cells Nanomed. Biotechnol. 2017;45(6):1–7. DOI: 10.1080/21691401.2017.1299159Namdari M., Cheraghi M., Negahdari B., Eatemadi A., Daraee H. Recent advances in magnetoliposome for heart drug delivery. Artif. Cells Nanomed. Biotechnol. 2017;45(6):1–7. DOI: 10.1080/21691401.2017.1299159Somasuntharam I., Yehl K., Carroll S.L., Maxwell J.T., Martinez M.D., Che P.L., Brown M.E., Salaita K., Davis M.E. Knockdown of TNF-α by DNAzyme gold nanoparticles as an anti-infl ammatory therapy for myocardial infarction. Biomaterials. 2016;83:12–22. DOI: 10.1016/j.biomaterials.2015.12.022Somasuntharam I., Yehl K., Carroll S.L., Maxwell J.T., Martinez M.D., Che P.L., Brown M.E., Salaita K., Davis M.E. Knockdown of TNF-α by DNAzyme gold nanoparticles as an anti-infl ammatory therapy for myocardial infarction. Biomaterials. 2016;83:12–22. DOI: 10.1016/j.biomaterials.2015.12.022Zhu K., Wu M., Lai H., Guo C., Li J., Wang Y., Chen Y., Wang C., Shi J. Nanoparticle-enhanced generation of gene-transfected mesenchymal stem cells for in vivo cardiac repair. Biomaterials. 2016;74:188–99. DOI: 10.1016/j.biomaterials.2015.10.010Zhu K., Wu M., Lai H., Guo C., Li J., Wang Y., Chen Y., Wang C., Shi J. Nanoparticle-enhanced generation of gene-transfected mesenchymal stem cells for in vivo cardiac repair. Biomaterials. 2016;74:188–99. DOI: 10.1016/j.biomaterials.2015.10.010Takakura Y., Takahashi Y. Strategies for persistent retention of macromolecules and nanoparticles in the blood circulation. J. Control. Release. 2022;350:486–493. DOI: 10.1016/j.jconrel.2022.05.063Takakura Y., Takahashi Y. Strategies for persistent retention of macromolecules and nanoparticles in the blood circulation. J. Control. Release. 2022;350:486–493. DOI: 10.1016/j.jconrel.2022.05.063Evers M.J.W., Du W., Yang Q., Kooijmans S.A.A., Vink A., van Steenbergen M., Vader P., de Jager S.C.A., Fuchs SA., Mastrobattista E., Sluijter J.P.G., Lei Z., Schiffelers R. Delivery of modifi ed mRNA to damaged myocardium by systemic administration of lipid nanoparticles. J. Control. Release. 2022;343:207–216. DOI: 10.1016/j.jconrel.2022.01.027Evers M.J.W., Du W., Yang Q., Kooijmans S.A.A., Vink A., van Steenbergen M., Vader P., de Jager S.C.A., Fuchs SA., Mastrobattista E., Sluijter J.P.G., Lei Z., Schiffelers R. Delivery of modifi ed mRNA to damaged myocardium by systemic administration of lipid nanoparticles. J. Control. Release. 2022;343:207–216. DOI: 10.1016/j.jconrel.2022.01.027Asanuma H., Sanada S., Yoshitomi T., Sasaki H., Takahama H., Ihara M., Takahama H., Shinozaki Y., Mori H., Asakura M., Nakano A., Sugimachi M., Asano Y., Minamino T., Takashima S., Nagasaki Y., Kitakaze M. Novel synthesized radical-containing nanoparticles limit infarct size following ischemia and reperfusion in canine hearts. Cardiovasc. Drugs Ther. 2017;31(5–6):501–510. DOI: 10.1007/s10557–017–6758–6Asanuma H., Sanada S., Yoshitomi T., Sasaki H., Takahama H., Ihara M., Takahama H., Shinozaki Y., Mori H., Asakura M., Nakano A., Sugimachi M., Asano Y., Minamino T., Takashima S., Nagasaki Y., Kitakaze M. Novel synthesized radical-containing nanoparticles limit infarct size following ischemia and reperfusion in canine hearts. Cardiovasc. Drugs Ther. 2017;31(5–6):501–510. DOI: 10.1007/s10557–017–6758–6Allijn I.E., Czarny B.M.S., Wang X., Chong S.Y., Weiler M., da Silva A.E., Metselaar J.M., Lam C.S.P., Pastorin G., de Kleijn D.P.V., Storm G., Wang J.W., Schiffelers R.M. Liposome encapsulated berberine treatment attenuates cardiac dysfunction after myocardial infarction. J. Control Release. 2017;247:127–133. DOI: 10.1016/j.jconrel.2016.12.042Allijn I.E., Czarny B.M.S., Wang X., Chong S.Y., Weiler M., da Silva A.E., Metselaar J.M., Lam C.S.P., Pastorin G., de Kleijn D.P.V., Storm G., Wang J.W., Schiffelers R.M. Liposome encapsulated berberine treatment attenuates cardiac dysfunction after myocardial infarction. J. Control Release. 2017;247:127–133. DOI: 10.1016/j.jconrel.2016.12.042Paulis L.E., Geelen T., Kuhlmann M.T., Coolen B.F., Schäfers M., Nicolay K., Strijkers G.J. Distribution of lipid-based nanoparticles to infarcted myocardium with potential application for MRI-monitored drug delivery. J. Control. Release. 2012;162(2):276–85. DOI: 10.1016/j.jconrel.2012.06.035Paulis L.E., Geelen T., Kuhlmann M.T., Coolen B.F., Schäfers M., Nicolay K., Strijkers G.J. Distribution of lipid-based nanoparticles to infarcted myocardium with potential application for MRI-monitored drug delivery. J. Control. Release. 2012;162(2):276–85. DOI: 10.1016/j.jconrel.2012.06.035Díez-Pascual A.M. Surface engineering of nanomaterials with polymers, biomolecules, and small ligands for nanomedicine. Materials (Basel). 2022;15(9):3251. DOI: 10.3390/ma15093251Díez-Pascual A.M. Surface engineering of nanomaterials with polymers, biomolecules, and small ligands for nanomedicine. Materials (Basel). 2022;15(9):3251. DOI: 10.3390/ma15093251Anselmo A.C., Mitragotri S. Cell-mediated delivery of nanoparticles: taking advantage of circulatory cells to target nanoparticles. J. Control. Release. 2014;190:531–41. DOI: 10.1016/j.jconrel.2014.03.050Anselmo A.C., Mitragotri S. Cell-mediated delivery of nanoparticles: taking advantage of circulatory cells to target nanoparticles. J. Control. Release. 2014;190:531–41. DOI: 10.1016/j.jconrel.2014.03.050Ferreira M.P., Ranjan S., Correia A.M., Mäkilä E.M., Kinnunen S.M., Zhang H., Shahbazi M.A., Almeida P.V., Salonen J.J., Ruskoaho H.J., Airaksinen A.J., Hirvonen J.T., Santos H.A. In vitro and in vivo assessment of heart-homing porous silicon nanoparticles. Biomaterials. 2016;94:93–104. DOI: 10.1016/j.biomaterials.2016.03.046Ferreira M.P., Ranjan S., Correia A.M., Mäkilä E.M., Kinnunen S.M., Zhang H., Shahbazi M.A., Almeida P.V., Salonen J.J., Ruskoaho H.J., Airaksinen A.J., Hirvonen J.T., Santos H.A. In vitro and in vivo assessment of heart-homing porous silicon nanoparticles. Biomaterials. 2016;94:93–104. DOI: 10.1016/j.biomaterials.2016.03.046Jaiswal S., Rajnikanth P.S., Thakur S., Deepak P., Anand S. A Review on novel ligand targeted delivery for cardiovascular disorder. Curr. Drug. Deliv. 2021;18(8):1094–1104. DOI: 10.2174/1567201818666210301095046Jaiswal S., Rajnikanth P.S., Thakur S., Deepak P., Anand S. A Review on novel ligand targeted delivery for cardiovascular disorder. Curr. Drug. Deliv. 2021;18(8):1094–1104. DOI: 10.2174/1567201818666210301095046Ruckenstein E., Li Z.F. Surface modifi cation and functionalization through the self-assembled monolayer and graft polymerization. Adv. Colloid. Interface Sci. 2005;113(1):43–63. DOI: 10.1016/j.cis.2004.07.009Ruckenstein E., Li Z.F. Surface modifi cation and functionalization through the self-assembled monolayer and graft polymerization. Adv. Colloid. Interface Sci. 2005;113(1):43–63. DOI: 10.1016/j.cis.2004.07.009Torchilin V.P. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat. Rev. Drug. Discov. 2014;13(11):813–27. DOI: 10.1038/nrd4333Torchilin V.P. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat. Rev. Drug. Discov. 2014;13(11):813–27. DOI: 10.1038/nrd4333Verma V.K., Kamaraju S.R., Kancherla R., Kona L.K., Beevi S.S., Debnath T., Usha S.P., Vadapalli R., Arbab A.S., Chelluri L.K. Fluorescent magnetic iron oxide nanoparticles for cardiac precursor cell selection from stromal vascular fraction and optimization for magnetic resonance imaging. Int. J. Nanomedicine. 2015;10:711–26. DOI: 10.2147/IJN.S75445Verma V.K., Kamaraju S.R., Kancherla R., Kona L.K., Beevi S.S., Debnath T., Usha S.P., Vadapalli R., Arbab A.S., Chelluri L.K. Fluorescent magnetic iron oxide nanoparticles for cardiac precursor cell selection from stromal vascular fraction and optimization for magnetic resonance imaging. Int. J. Nanomedicine. 2015;10:711–26. DOI: 10.2147/IJN.S75445Peet C., Ivetic A., Bromage D.I., Shah A.M. Cardiac monocytes and macrophages after myocardial infarction. Cardiovasc. Res. 2020;116(6):1101–1112. DOI: 10.1093/cvr/cvz336Peet C., Ivetic A., Bromage D.I., Shah A.M. Cardiac monocytes and macrophages after myocardial infarction. Cardiovasc. Res. 2020;116(6):1101–1112. DOI: 10.1093/cvr/cvz336Fan C., Oduk Y., Zhao M., Lou X., Tang Y., Pretorius D., Valarmathi M.T., Walcott G.P., Yang J., Menasche P., Krishnamurthy P., Zhu W., Zhang J. Myocardial protection by nanomaterials formulated with CHIR99021 and FGF1. JCI Insight. 2020;5(12):e132796. DOI: 10.1172/jci.insight.132796Fan C., Oduk Y., Zhao M., Lou X., Tang Y., Pretorius D., Valarmathi M.T., Walcott G.P., Yang J., Menasche P., Krishnamurthy P., Zhu W., Zhang J. Myocardial protection by nanomaterials formulated with CHIR99021 and FGF1. JCI Insight. 2020;5(12):e132796. DOI: 10.1172/jci.insight.132796Du J., Zheng L., Gao P., Yang H., Yang W.J., Guo F., Liang R., Feng M., Wang Z., Zhang Z., Bai L., Bu Y., Xing S., Zheng W., Wang X., Quan L., Hu X., Wu H., Chen Z., Chen L., Wei K., Zhang Z., Zhu X., Zhang X., Tu Q., Zhao S.M., Lei X., Xiong J.W. A small-molecule cocktail promotes mammalian cardiomyocyte proliferation and heart regeneration. Cell. Stem. Cell. 2022;29(4):545– 558.e13. DOI: 10.1016/j.stem.2022.03.009Du J., Zheng L., Gao P., Yang H., Yang W.J., Guo F., Liang R., Feng M., Wang Z., Zhang Z., Bai L., Bu Y., Xing S., Zheng W., Wang X., Quan L., Hu X., Wu H., Chen Z., Chen L., Wei K., Zhang Z., Zhu X., Zhang X., Tu Q., Zhao S.M., Lei X., Xiong J.W. A small-molecule cocktail promotes mammalian cardiomyocyte proliferation and heart regeneration. Cell. Stem. Cell. 2022;29(4):545– 558.e13. DOI: 10.1016/j.stem.2022.03.009Molavi B., Chen J., Mehta J.L. Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK. Am. J. Physiol. Heart Circ. Physiol. 2006;291(2):H687–93. DOI: 10.1152/ajpheart.00926.2005Molavi B., Chen J., Mehta J.L. Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK. Am. J. Physiol. Heart Circ. Physiol. 2006;291(2):H687–93. DOI: 10.1152/ajpheart.00926.2005Yang B.C., Phillips M.I., Ambuehl P.E., Shen L.P., Mehta P., Mehta J.L. Increase in angiotensin II type 1 receptor expression immediately after ischemia-reperfusion in isolated rat hearts. Circulation. 1997;96(3):922–6. DOI: 10.1161/01.cir.96.3.922Yang B.C., Phillips M.I., Ambuehl P.E., Shen L.P., Mehta P., Mehta J.L. Increase in angiotensin II type 1 receptor expression immediately after ischemia-reperfusion in isolated rat hearts. Circulation. 1997;96(3):922–6. DOI: 10.1161/01.cir.96.3.922Dvir T., Bauer M., Schroeder A., Tsui J.H., Anderson D.G., Langer R., Liao R., Kohane D.S. Nanoparticles targeting the infarcted heart. Nano Lett. 2011; 1(10):4411–4. DOI: 10.1021/nl2025882Dvir T., Bauer M., Schroeder A., Tsui J.H., Anderson D.G., Langer R., Liao R., Kohane D.S. Nanoparticles targeting the infarcted heart. Nano Lett. 2011; 1(10):4411–4. DOI: 10.1021/nl2025882Xue X., Shi X., Dong H., You S., Cao H., Wang K., Wen Y., Shi D., He B., Li Y. Delivery of microRNA-1 inhibitor by dendrimer-based nanovector: An early targeting therapy for myocardial infarction in mice. Nanomedicine. 2018;14(2):619–631. DOI: 10.1016/j.nano.2017.12.004Xue X., Shi X., Dong H., You S., Cao H., Wang K., Wen Y., Shi D., He B., Li Y. Delivery of microRNA-1 inhibitor by dendrimer-based nanovector: An early targeting therapy for myocardial infarction in mice. Nanomedicine. 2018;14(2):619–631. DOI: 10.1016/j.nano.2017.12.004Gasc J.M., Shanmugam S., Sibony M., Corvol P. Tissue-specifi c expression of type 1 angiotensin II receptor subtypes. An in situ hybridization study. Hypertension. 1994;24(5):531–7. DOI: 10.1161/01.hyp.24.5.531Gasc J.M., Shanmugam S., Sibony M., Corvol P. Tissue-specifi c expression of type 1 angiotensin II receptor subtypes. An in situ hybridization study. Hypertension. 1994;24(5):531–7. DOI: 10.1161/01.hyp.24.5.531McGuire M.J., Samli K.N., Johnston S.A., Brown K.C. In vitro selection of a peptide with high selectivity for cardiomyocytes in vivo. J. Mol. Biol. 2004;342(1):171–82. DOI: 10.1016/j.jmb.2004.06.029McGuire M.J., Samli K.N., Johnston S.A., Brown K.C. In vitro selection of a peptide with high selectivity for cardiomyocytes in vivo. J. Mol. Biol. 2004;342(1):171–82. DOI: 10.1016/j.jmb.2004.06.029Ikuta T., Sogawa N., Ariga H., Ikemura T., Matsumoto K. Structural analysis of mouse tenascin-X: evolutionary aspects of reduplication of FNIII repeats in the tenascin gene family. Gene. 1998;217(1–2):1– 13. DOI: 10.1016/s0378-1119(98)00355-2Ikuta T., Sogawa N., Ariga H., Ikemura T., Matsumoto K. Structural analysis of mouse tenascin-X: evolutionary aspects of reduplication of FNIII repeats in the tenascin gene family. Gene. 1998;217(1–2):1– 13. DOI: 10.1016/s0378-1119(98)00355-2Hu B., Boakye-Yiadom KO., Yu W., Yuan Z.W., Ho W., Xu X., Zhang X.Q. Nanomedicine Approaches for Advanced Diagnosis and Treatment of therosclerosis and Related Ischemic Diseases. Adv. Healthc Mater. 2020;9(16):e2000336. DOI: 10.1002/adhm.202000336Hu B., Boakye-Yiadom KO., Yu W., Yuan Z.W., Ho W., Xu X., Zhang X.Q. Nanomedicine Approaches for Advanced Diagnosis and Treatment of therosclerosis and Related Ischemic Diseases. Adv. Healthc Mater. 2020;9(16):e2000336. DOI: 10.1002/adhm.202000336Li R., He Y., Zhang S., Qin J., Wang J. Cell membrane-based nanoparticles: a new biomimetic platform for tumor diagnosis and treatment. Acta Pharm. Sin. B. 2018;8(1):14–22. DOI: 10.1016/j.apsb.2017.11.009Li R., He Y., Zhang S., Qin J., Wang J. Cell membrane-based nanoparticles: a new biomimetic platform for tumor diagnosis and treatment. Acta Pharm. Sin. B. 2018;8(1):14–22. DOI: 10.1016/j.apsb.2017.11.009Radecke C.E., Warrick A.E., Singh G.D., Rogers J.H., Simon S.I., Armstrong E.J. Coronary artery endothelial cells and microparticles increase expression of VCAM-1 in myocardial infarction. Thromb. Haemost. 2015;113(3):605–16. DOI: 10.1160/TH14-02-0151Radecke C.E., Warrick A.E., Singh G.D., Rogers J.H., Simon S.I., Armstrong E.J. Coronary artery endothelial cells and microparticles increase expression of VCAM-1 in myocardial infarction. Thromb. Haemost. 2015;113(3):605–16. DOI: 10.1160/TH14-02-0151Wei Y., Zhu M., Li S., Hong T., Guo X., Li Y., Liu Y., Hou X., He B. Engineered biomimetic nanoplatform protects the myocardium against ischemia/reperfusion injury by inhibiting pyroptosis. ACS App. Mater. Interfaces. 2021;13(29):33756–33766. DOI: 10.1021/acsami.1c03421.Wei Y., Zhu M., Li S., Hong T., Guo X., Li Y., Liu Y., Hou X., He B. Engineered biomimetic nanoplatform protects the myocardium against ischemia/reperfusion injury by inhibiting pyroptosis. ACS App. Mater. Interfaces. 2021;13(29):33756–33766. DOI: 10.1021/acsami.1c03421.Neves K.B., Rios F.J., Sevilla-Montero J., Montezano A.C., Touyz R.M. Exosomes and the cardiovascular system: role in car diovas cular health and disease. J. Physiol. 2022. DOI: 10.1113/JP282054Neves K.B., Rios F.J., Sevilla-Montero J., Montezano A.C., Touyz R.M. Exosomes and the cardiovascular system: role in car diovas cular health and disease. J. Physiol. 2022. DOI: 10.1113/JP282054Valadi H., Ekström K., Bossios A., Sjöstrand M., Lee J.J., Lötvall J.O. Exosome–mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007;9(6):654–9. DOI: 10.1038/ncb1596Valadi H., Ekström K., Bossios A., Sjöstrand M., Lee J.J., Lötvall J.O. Exosome–mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007;9(6):654–9. DOI: 10.1038/ncb1596Xu R., Greening D.W., Zhu H.J., Takahashi N., Simpson R.J. Extracellular vesicle isolation and characterization: toward clinical application. J. Clin. Invest. 2016;126(4):1152–62. DOI: 10.1172/JCI81129Xu R., Greening D.W., Zhu H.J., Takahashi N., Simpson R.J. Extracellular vesicle isolation and characterization: toward clinical application. J. Clin. Invest. 2016;126(4):1152–62. DOI: 10.1172/JCI81129Liu S., Chen X., Bao L., Liu T., Yuan P., Yang X., Qiu X., Gooding J.J., Bai Y., Xiao J., Pu F., Jin Y. Treatment of infarcted heart tissue via the capture and local delivery of circulating exosomes through antibody-conjugated magnetic nanoparticles. Nat. Biomed. Eng. 2020;4(11):1063–1075. DOI: 10.1038/s41551–020–00637–1Liu S., Chen X., Bao L., Liu T., Yuan P., Yang X., Qiu X., Gooding J.J., Bai Y., Xiao J., Pu F., Jin Y. Treatment of infarcted heart tissue via the capture and local delivery of circulating exosomes through antibody-conjugated magnetic nanoparticles. Nat. Biomed. Eng. 2020;4(11):1063–1075. DOI: 10.1038/s41551–020–00637–1Ferreira M.P.A., Ranjan S., Kinnunen S., Correia A., Talman V., Mäkilä E., Barrios-Lopez B., Kemell M., Balasubramanian V., Salonen J., Hirvonen J., Ruskoaho H., Airaksinen A.J., Santos H.A. Drug-loaded multifunctional nanoparticles targeted to the endocardial layer of the injured heart modulate hypertrophic signaling. Small. 2017;13(33). DOI: 10.1002/smll.201701276Ferreira M.P.A., Ranjan S., Kinnunen S., Correia A., Talman V., Mäkilä E., Barrios-Lopez B., Kemell M., Balasubramanian V., Salonen J., Hirvonen J., Ruskoaho H., Airaksinen A.J., Santos H.A. Drug-loaded multifunctional nanoparticles targeted to the endocardial layer of the injured heart modulate hypertrophic signaling. Small. 2017;13(33). DOI: 10.1002/smll.201701276Yu J., Li W., Yu D. Atrial natriuretic peptide modifi ed oleate adenosine prodrug lipid nanocarriers for the treatment of myocardial infarction: in vitro and in vivo evaluation. Drug. Des. Devel. Ther. 2018;12:1697–1706. DOI: 10.2147/DDDT.S166749Yu J., Li W., Yu D. Atrial natriuretic peptide modifi ed oleate adenosine prodrug lipid nanocarriers for the treatment of myocardial infarction: in vitro and in vivo evaluation. Drug. Des. Devel. Ther. 2018;12:1697–1706. DOI: 10.2147/DDDT.S166749Jamasbi J., Ayabe K., Goto S., Nieswandt B., Peter K., Siess W. Platelet receptors as therapeutic targets: past, present and future. Thromb. Haemost. 2017;117(7):1249–1257. DOI: 10.1160/TH16-12-0911Jamasbi J., Ayabe K., Goto S., Nieswandt B., Peter K., Siess W. Platelet receptors as therapeutic targets: past, present and future. Thromb. Haemost. 2017;117(7):1249–1257. DOI: 10.1160/TH16-12-0911Hernández-Reséndiz S., Muñoz-Vega M., Contreras W.E., Crespo-Avilan G.E., Rodriguez-Montesinos J., Arias-Carrión O., Pérez-Méndez O., Boisvert W.A., Preissner K.T., Cabrera-Fuentes H.A. Responses of endothelial cells towards ischemic conditioning following acute myocardial infarction. Cond. Med. 2018;1(5):247–258.Hernández-Reséndiz S., Muñoz-Vega M., Contreras W.E., Crespo-Avilan G.E., Rodriguez-Montesinos J., Arias-Carrión O., Pérez-Méndez O., Boisvert W.A., Preissner K.T., Cabrera-Fuentes H.A. Responses of endothelial cells towards ischemic conditioning following acute myocardial infarction. Cond. Med. 2018;1(5):247–258.Li F., Liu D., Liu M., Ji Q., Zhang B., Mei Q., Cheng Y., Zhou S. Tregs biomimetic nanoparticle to reprogram infl ammatory and redox microenvironment in infarct tissue to treat myocardial ischemia reperfusion injury in mice. J. Nanobiotechnology. 2022;20(1):251. DOI: 10.1186/s12951-022-01445-2Li F., Liu D., Liu M., Ji Q., Zhang B., Mei Q., Cheng Y., Zhou S. Tregs biomimetic nanoparticle to reprogram infl ammatory and redox microenvironment in infarct tissue to treat myocardial ischemia reperfusion injury in mice. J. Nanobiotechnology. 2022;20(1):251. DOI: 10.1186/s12951-022-01445-2Zhou T., Yang X., Wang T., Xu M., Huang Z., Yu R., Jiang Y., Zhou Y., Shi J. Platelet–Membrane–Encapsulated Carvedilol with Improved Targeting Ability for Relieving Myocardial Ischemia–Reperfusion Injury. Membranes (Basel). 2022;12(6):605. DOI: 10.3390/membranes12060605Zhou T., Yang X., Wang T., Xu M., Huang Z., Yu R., Jiang Y., Zhou Y., Shi J. Platelet–Membrane–Encapsulated Carvedilol with Improved Targeting Ability for Relieving Myocardial Ischemia–Reperfusion Injury. Membranes (Basel). 2022;12(6):605. DOI: 10.3390/membranes12060605Tang J., Su T., Huang K., Dinh P.U., Wang Z., Vandergriff A., Hensley M.T., Cores J., Allen T., Li T., Sproul E., Mihalko E., Lobo L.J., Ruterbories L., Lynch A., Brown A., Caranasos T.G., Shen D., Stouffer G.A., Gu Z., Zhang J., Cheng K. Targeted repair of heart injury by stem cells fused with platelet nanovesicles. Nat. Biomed. Eng. 2018;2:17–26. DOI: 10.1038/s41551-017-0182-xTang J., Su T., Huang K., Dinh P.U., Wang Z., Vandergriff A., Hensley M.T., Cores J., Allen T., Li T., Sproul E., Mihalko E., Lobo L.J., Ruterbories L., Lynch A., Brown A., Caranasos T.G., Shen D., Stouffer G.A., Gu Z., Zhang J., Cheng K. Targeted repair of heart injury by stem cells fused with platelet nanovesicles. Nat. Biomed. Eng. 2018;2:17–26. DOI: 10.1038/s41551-017-0182-xValikeserlis I., Athanasiou A.A., Stakos D. Cellular mechanisms and pathways in myocardial reperfusion injury. Coron. Artery Dis. 2021;32(6):567–577. DOI: 10.1097/MCA.0000000000000997Valikeserlis I., Athanasiou A.A., Stakos D. Cellular mechanisms and pathways in myocardial reperfusion injury. Coron. Artery Dis. 2021;32(6):567–577. DOI: 10.1097/MCA.0000000000000997Konegawa Y., Kuwahara T., Jo J.I., Murata K., Takeda T., Ikeda T., Minatoya K., Masumoto H., Tabata Y. Pioglitazone-incorporated microspheres targeting macrophage polarization alleviates cardiac dysfunction after myocardial infarction. Eur. J. Cardiothorac. Surg. 2022;62(5):ezac414. DOI: 10.1093/ejcts/ezac414Konegawa Y., Kuwahara T., Jo J.I., Murata K., Takeda T., Ikeda T., Minatoya K., Masumoto H., Tabata Y. Pioglitazone-incorporated microspheres targeting macrophage polarization alleviates cardiac dysfunction after myocardial infarction. Eur. J. Cardiothorac. Surg. 2022;62(5):ezac414. DOI: 10.1093/ejcts/ezac414Nakano Y., Matoba T., Tokutome M., Funamoto D., Katsuki S., Ikeda G., Nagaoka K., Ishikita A., Nakano K., Koga J., Sunagawa K., Egashira K. Nanoparticle-mediated delivery of irbesartan induces cardioprotection from myocardial ischemia-reperfusion injury by antagonizing monocyte-mediated infl ammation. Sci. Rep. 2016;6:29601. DOI: 10.1038/srep29601Nakano Y., Matoba T., Tokutome M., Funamoto D., Katsuki S., Ikeda G., Nagaoka K., Ishikita A., Nakano K., Koga J., Sunagawa K., Egashira K. Nanoparticle-mediated delivery of irbesartan induces cardioprotection from myocardial ischemia-reperfusion injury by antagonizing monocyte-mediated infl ammation. Sci. Rep. 2016;6:29601. DOI: 10.1038/srep29601Tokutome M., Matoba T., Nakano Y., Okahara A., Fujiwara M., Koga J.I., Nakano K., Tsutsui H., Egashira K. Peroxisome proliferator-activated receptor-gamma targeting nanomedicine promotes cardiac healing after acute myocardial infarction by skewing monocyte/ macrophage polarization in preclinical animal models. Cardiovasc. Res. 2019;115(2):419–431. DOI: 10.1093/cvr/cvy200Tokutome M., Matoba T., Nakano Y., Okahara A., Fujiwara M., Koga J.I., Nakano K., Tsutsui H., Egashira K. Peroxisome proliferator-activated receptor-gamma targeting nanomedicine promotes cardiac healing after acute myocardial infarction by skewing monocyte/ macrophage polarization in preclinical animal models. Cardiovasc. Res. 2019;115(2):419–431. DOI: 10.1093/cvr/cvy200Swirski F.K., Nahrendorf M., Etzrodt M., Wildgruber M., Cortez-Retamozo V., Panizzi P., Figueiredo J.L., Kohler R.H., Chudnovskiy A., Waterman P., Aikawa E., Mempel T.R., Libby P., Weissleder R., Pittet M.J. Identifi cation of splenic reservoir monocytes and their deployment to infl ammatory sites. Science. 2009;325(5940):612–6. DOI: 10.1126/science.1175202Swirski F.K., Nahrendorf M., Etzrodt M., Wildgruber M., Cortez-Retamozo V., Panizzi P., Figueiredo J.L., Kohler R.H., Chudnovskiy A., Waterman P., Aikawa E., Mempel T.R., Libby P., Weissleder R., Pittet M.J. Identifi cation of splenic reservoir monocytes and their deployment to infl ammatory sites. Science. 2009;325(5940):612–6. DOI: 10.1126/science.1175202Wang J., Seo M.J., Deci M.B., Weil B.R., Canty J.M., Nguyen J. Effect of CCR2 inhibitor-loaded lipid micelles on infl ammatory cell migration and cardiac function after myocardial infarction. Int. J. Nanomedicine. 2018;13:6441–6451. DOI: 10.2147/IJN.S178650Wang J., Seo M.J., Deci M.B., Weil B.R., Canty J.M., Nguyen J. Effect of CCR2 inhibitor-loaded lipid micelles on infl ammatory cell migration and cardiac function after myocardial infarction. Int. J. Nanomedicine. 2018;13:6441–6451. DOI: 10.2147/IJN.S178650Puré E., Cuff C.A. A crucial role for CD44 in infl ammation. Trends Mol. Med. 2001;7(5):213–21. DOI: 10.1016/s1471-4914(01)01963-3Puré E., Cuff C.A. A crucial role for CD44 in infl ammation. Trends Mol. Med. 2001;7(5):213–21. DOI: 10.1016/s1471-4914(01)01963-3Glucksam–Galnoy Y., Zor T., Margalit R. Hyaluronan-modifi ed and regular multilamellar liposomes provide sub-cellular targeting to macrophages, without eliciting a pro-infl ammatory response. J. Control. Release. 2012;160(2):388–93. DOI: 10.1016/j.jconrel.2011.10.008Glucksam–Galnoy Y., Zor T., Margalit R. Hyaluronan-modifi ed and regular multilamellar liposomes provide sub-cellular targeting to macrophages, without eliciting a pro-infl ammatory response. J. Control. Release. 2012;160(2):388–93. DOI: 10.1016/j.jconrel.2011.10.008Ben-Mordechai T., Kain D., Holbova R., Landa N., Levin L.P., Elron-Gross I., Glucksam-Galnoy Y., Feinberg M.S., Margalit R., Leor J. Targeting and modulating infarct macrophages with hemin formulated in designed lipid-based particles improves cardiac remodeling and function. J. Control Release. 2017;257:21–31. DOI: 10.1016/j.jconrel.2017.01.001Ben-Mordechai T., Kain D., Holbova R., Landa N., Levin L.P., Elron-Gross I., Glucksam-Galnoy Y., Feinberg M.S., Margalit R., Leor J. Targeting and modulating infarct macrophages with hemin formulated in designed lipid-based particles improves cardiac remodeling and function. J. Control Release. 2017;257:21–31. DOI: 10.1016/j.jconrel.2017.01.001Соловаров И.С., Хаснатинов М.А., Ляпунова Н.А., Кондратов И.Г., Данчинова Г.А. Разработка подходов к селекции ДНК-аптамеров на основе мембранной ультрафильтрации комплекса аптамер–мишень. Acta Biomedica Scientifi ca. 2022;7(6):119–127.Solovarov I.S., Khasnatinov M.A., Liapunova N.A., Kondratov I.G., Danchinova G.A. Development of DNA aptamer selection approach based on membrane ultrafi ltration of aptamer/target complex. Acta Biomedica Scientifi ca. 2022;7(6):119– 127. (In Russian) DOI: 10.29413/ABS.2022–7.6.12Huang S.S., Lee K.J., Chen H.C., Prajnamitra R.P., Hsu C.H., Jian C.B., Yu X.E., Chueh D.Y., Kuo C.W., Chiang T.C., Choong O.K., Huang S.C., Beh C.Y., Chen L.L., Lai J.J., Chen P., Kamp T.J., Tien Y.W., Lee H.M., Hsieh P.C. Immune cell shuttle for precise delivery of nanotherapeutics for heart disease and cancer. Sci. Adv. 2021;7(17):eabf2400. DOI: 10.1126/sciadv.abf2400Huang S.S., Lee K.J., Chen H.C., Prajnamitra R.P., Hsu C.H., Jian C.B., Yu X.E., Chueh D.Y., Kuo C.W., Chiang T.C., Choong O.K., Huang S.C., Beh C.Y., Chen L.L., Lai J.J., Chen P., Kamp T.J., Tien Y.W., Lee H.M., Hsieh P.C. Immune cell shuttle for precise delivery of nanotherapeutics for heart disease and cancer. Sci. Adv. 2021;7(17):eabf2400. DOI: 10.1126/sciadv.abf2400Wong D.J., Park D.D., Park S.S., Haller C.A., Chen J., Dai E., Liu L., Mandhapati A.R., Eradi P., Dhakal B., Wever W.J., Hanes M., Sun L., Cummings R.D., Chaikof E.L. A PSGL–1 glycomimetic reduces thrombus burden without affecting hemostasis. Blood. 2021;138(13):1182–1193. DOI: 10.1182/blood.2020009428Wong D.J., Park D.D., Park S.S., Haller C.A., Chen J., Dai E., Liu L., Mandhapati A.R., Eradi P., Dhakal B., Wever W.J., Hanes M., Sun L., Cummings R.D., Chaikof E.L. A PSGL–1 glycomimetic reduces thrombus burden without affecting hemostasis. Blood. 2021;138(13):1182–1193. DOI: 10.1182/blood.2020009428Sarma J., Laan C.A., Alam S., Jha A., Fox K.A. Dransfi eld I. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation. 2002;105(18):2166–71. DOI: 10.1161/01.cir.0000015700.27754.6fSarma J., Laan C.A., Alam S., Jha A., Fox K.A. Dransfi eld I. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation. 2002;105(18):2166–71. DOI: 10.1161/01.cir.0000015700.27754.6fAn G., Wang H., Tang R., Yago T., McDaniel J.M., McGee S., Huo Y., Xia L. P-selectin glycoprotein ligand-1 is highly expressed on Ly-6Chi monocytes and a major determinant for Ly-6Chi monocyte recruitment to sites of atherosclerosis in mice. Circulation. 2008;117(25):3227–37. DOI: 10.1161/CIRCULATIONAHA.108.771048An G., Wang H., Tang R., Yago T., McDaniel J.M., McGee S., Huo Y., Xia L. P-selectin glycoprotein ligand-1 is highly expressed on Ly-6Chi monocytes and a major determinant for Ly-6Chi monocyte recruitment to sites of atherosclerosis in mice. Circulation. 2008;117(25):3227–37. DOI: 10.1161/CIRCULATIONAHA.108.771048Huo Y., Schober A., Forlow S.B., Smith D.F., Hyman M.C., Jung S., Littman D.R., Weber C., Ley K. Circulating activated platelets exacerbate atherosclerosis in mice defi cient in apolipoprotein E. Nat. Med. 2003;9(1):61–7. DOI: 10.1038/nm810Huo Y., Schober A., Forlow S.B., Smith D.F., Hyman M.C., Jung S., Littman D.R., Weber C., Ley K. Circulating activated platelets exacerbate atherosclerosis in mice defi cient in apolipoprotein E. Nat. Med. 2003;9(1):61–7. DOI: 10.1038/nm810Cheng B., Toh E.K., Chen K.H., Chang Y.C., Hu C.J., Wu H.C., Chau L.Y., Chen P., Hsieh P.C. Biomimicking platelet-monocyte interactions as a novel targeting strategy for heart healing. Adv. Healthc Mater. 2016;5(20):2686–2697. DOI: 10.1002/adhm.201600724Cheng B., Toh E.K., Chen K.H., Chang Y.C., Hu C.J., Wu H.C., Chau L.Y., Chen P., Hsieh P.C. Biomimicking platelet-monocyte interactions as a novel targeting strategy for heart healing. Adv. Healthc Mater. 2016;5(20):2686–2697. DOI: 10.1002/adhm.201600724Liu Y., Gao XM., Fang L., Jennings N.L., Su Y., Q X., Samson A.L., Kiriazis H., Wang X.F., Shan L., Sturgeon S.A., Medcalf R.L., Jackson S.P., Dart A.M., Du X.J. Novel role of platelets in mediating infl ammatory responses and ventricular rupture or remodeling following myocardial infarction. Arterioscler Thromb Vasc Biol. 2011;31(4):834–41. DOI: 10.1161/ATVBAHA.110.220467Liu Y., Gao XM., Fang L., Jennings N.L., Su Y., Q X., Samson A.L., Kiriazis H., Wang X.F., Shan L., Sturgeon S.A., Medcalf R.L., Jackson S.P., Dart A.M., Du X.J. Novel role of platelets in mediating infl ammatory responses and ventricular rupture or remodeling following myocardial infarction. Arterioscler Thromb Vasc Biol. 2011;31(4):834–41. DOI: 10.1161/ATVBAHA.110.220467Tan H., Song Y., Chen J., Zhang N., Wang Q., Li Q., Gao J., Yang H., Dong Z., Weng X., Wang Z., Sun D., Yakufu W., Pang Z., Huang Z., Ge J. Platelet-like fusogenic liposome-mediated targeting delivery of mir-21 improves myocardial remodeling by reprogramming macrophages post myocardial ischemia-reperfusion injury. Adv. Sci. (Weinh). 2021;8(15):e2100787. DOI: 10.1002/advs.202100787Tan H., Song Y., Chen J., Zhang N., Wang Q., Li Q., Gao J., Yang H., Dong Z., Weng X., Wang Z., Sun D., Yakufu W., Pang Z., Huang Z., Ge J. Platelet-like fusogenic liposome-mediated targeting delivery of mir-21 improves myocardial remodeling by reprogramming macrophages post myocardial ischemia-reperfusion injury. Adv. Sci. (Weinh). 2021;8(15):e2100787. DOI: 10.1002/advs.202100787Schanze N., Bode C., Duerschmied D. Platelet contributions to myocardial ischemia/reperfusion injury. Front Immunol. 2019;10:1260. DOI: 10.3389/fimmu.2019.01260Schanze N., Bode C., Duerschmied D. Platelet contributions to myocardial ischemia/reperfusion injury. Front Immunol. 2019;10:1260. DOI: 10.3389/fimmu.2019.01260Keykhaei M., Ashraf H., Rashedi S., Farrokhpour H., Heidari B., Zokaei S., Bagheri S., Foroumadi R., Asgarian S., Amirian A., Saleh S.K., James S. Differences in the 2020 ESC Versus 2015 ESC and 2014 ACC/AHA Guidelines on the management of acute coronary syndromes in patients presenting without persistent st-segment elevation. Curr. Atheroscler. Rep. 2021;23(12):77. DOI: 10.1007/s11883–021–00976–7Keykhaei M., Ashraf H., Rashedi S., Farrokhpour H., Heidari B., Zokaei S., Bagheri S., Foroumadi R., Asgarian S., Amirian A., Saleh S.K., James S. Differences in the 2020 ESC Versus 2015 ESC and 2014 ACC/AHA Guidelines on the management of acute coronary syndromes in patients presenting without persistent st-segment elevation. Curr. Atheroscler. Rep. 2021;23(12):77. DOI: 10.1007/s11883–021–00976–7Xie S., Mo C., Cao W., Xie S., Li S., Zhang Z., Li X. Bacteria-propelled microtubular motors for effi cient penetration and targeting delivery of thrombolytic agents. Acta Biomater. 2022;142:49–59. DOI: 10.1016/j.actbio.2022.02.008Xie S., Mo C., Cao W., Xie S., Li S., Zhang Z., Li X. Bacteria-propelled microtubular motors for effi cient penetration and targeting delivery of thrombolytic agents. Acta Biomater. 2022;142:49–59. DOI: 10.1016/j.actbio.2022.02.008Juenet M., Aid-Launais R., Li B., Berger A., Aerts J., Ollivier V., Nicoletti A., Letourneur D., Chauvierre C. Thrombolytic therapy based on fucoidan-functionalized polymer nanoparticles targeting P-selectin. Biomaterials. 2018;156:204–216. DOI: 10.1016/j.biomaterials.2017.11.047Juenet M., Aid-Launais R., Li B., Berger A., Aerts J., Ollivier V., Nicoletti A., Letourneur D., Chauvierre C. Thrombolytic therapy based on fucoidan-functionalized polymer nanoparticles targeting P-selectin. Biomaterials. 2018;156:204–216. DOI: 10.1016/j.biomaterials.2017.11.047Chen Y., Zhao Y., Chen W., Xie L., Zhao Z.A., Yang J., Chen Y., Lei W., Shen Z. MicroRNA-133 overexpression promotes the therapeutic effi cacy of mesenchymal stem cells on acute myocardial infarction. Stem Cell Res. Ther. 2017;8(1):268. DOI: 10.1186/s13287-017-0722-zChen Y., Zhao Y., Chen W., Xie L., Zhao Z.A., Yang J., Chen Y., Lei W., Shen Z. MicroRNA-133 overexpression promotes the therapeutic effi cacy of mesenchymal stem cells on acute myocardial infarction. Stem Cell Res. Ther. 2017;8(1):268. DOI: 10.1186/s13287-017-0722-zYu B.T., Yu N., Wang Y., Zhang H., Wan K., Sun X., Zhang C.S. Role of miR-133a in regulating TGF-β1 signaling pathway in myocardial fi brosis after acute myocardial infarction in rats. Eur. Rev. Med. Pharmacol. Sci. 2019;23(19):8588–8597. DOI: 10.26355/eurrev_201910_19175Yu B.T., Yu N., Wang Y., Zhang H., Wan K., Sun X., Zhang C.S. Role of miR-133a in regulating TGF-β1 signaling pathway in myocardial fi brosis after acute myocardial infarction in rats. Eur. Rev. Med. Pharmacol. Sci. 2019;23(19):8588–8597. DOI: 10.26355/eurrev_201910_19175Zhang X.G., Wang L.Q., Guan H.L. Investigating the expression of miRNA-133 in animal models of myocardial infarction and its effect on cardiac function. Eur. Rev. Med. Pharmacol. Sci. 2019;23(13):5934–5940. DOI: 10.26355/eurrev_201907_18338Zhang X.G., Wang L.Q., Guan H.L. Investigating the expression of miRNA-133 in animal models of myocardial infarction and its effect on cardiac function. Eur. Rev. Med. Pharmacol. Sci. 2019;23(13):5934–5940. DOI: 10.26355/eurrev_201907_18338Sun B., Liu S., Hao R., Dong X., Fu L., Han B. RGD-PEG-PLA Delivers MiR-133 to Infarct Lesions of Acute Myocardial Infarction Model Rats for Cardiac Protection. Pharmaceutics. 2020;12(6):575. DOI: 10.3390/pharmaceutics12060575Sun B., Liu S., Hao R., Dong X., Fu L., Han B. RGD-PEG-PLA Delivers MiR-133 to Infarct Lesions of Acute Myocardial Infarction Model Rats for Cardiac Protection. Pharmaceutics. 2020;12(6):575. DOI: 10.3390/pharmaceutics12060575Duro-Castano A., Gallon E., Decker C., Vicent M.J. Modulating angiogenesis with integrin-targeted nanomedicines. Adv. Drug. Deliv. Rev. 2017;119:101–119. DOI: 10.1016/j.addr.2017.05.008Duro-Castano A., Gallon E., Decker C., Vicent M.J. Modulating angiogenesis with integrin-targeted nanomedicines. Adv. Drug. Deliv. Rev. 2017;119:101–119. DOI: 10.1016/j.addr.2017.05.008Halestrap A.P. Mitochondrial permeability: dual role for the ADP/ ATP translocator? Nature. 2004;430(7003):1. DOI: 10.1038/nature02816Halestrap A.P. Mitochondrial permeability: dual role for the ADP/ ATP translocator? Nature. 2004;430(7003):1. DOI: 10.1038/nature02816Huo J., Lu S., Kwong J.Q., Bround M.J., Grimes K.M., Sargent M.A., Brown M.E., Davis M.E., Bers D.M., Molkentin J.D. MCUb induction protects the heart from postischemic remodeling. Circ. Res. 2020;127(3):379–390. DOI: 10.1161/CIRCRESAHA.119.316369Huo J., Lu S., Kwong J.Q., Bround M.J., Grimes K.M., Sargent M.A., Brown M.E., Davis M.E., Bers D.M., Molkentin J.D. MCUb induction protects the heart from postischemic remodeling. Circ. Res. 2020;127(3):379–390. DOI: 10.1161/CIRCRESAHA.119.316369Ikeda G., Matoba T., Nakano Y., Nagaoka K., Ishikita A., Nakano K., Funamoto D., Sunagawa K., Egashira K. Nanoparticle-mediated targeting of cyclosporine a enhances cardioprotection against ischemia-reperfusion injury through inhibition of mitochondrial permeability transition pore opening. Sci. Rep. 2016;6:20467. DOI: 10.1038/srep20467Ikeda G., Matoba T., Nakano Y., Nagaoka K., Ishikita A., Nakano K., Funamoto D., Sunagawa K., Egashira K. Nanoparticle-mediated targeting of cyclosporine a enhances cardioprotection against ischemia-reperfusion injury through inhibition of mitochondrial permeability transition pore opening. Sci. Rep. 2016;6:20467. DOI: 10.1038/srep20467Zhang C.X., Cheng Y., Liu D.Z., Liu M., Cui H., Zhang B.L., Mei Q.B., Zhou S.Y. Mitochondria-targeted cyclosporin A deli very system to treat myocardial ischemia reperfusion injury of rats. J. Nanobiotechnology. 2019;17(1):18. DOI: 10.1186/s12951-019-0451-9Zhang C.X., Cheng Y., Liu D.Z., Liu M., Cui H., Zhang B.L., Mei Q.B., Zhou S.Y. Mitochondria-targeted cyclosporin A deli very system to treat myocardial ischemia reperfusion injury of rats. J. Nanobiotechnology. 2019;17(1):18. DOI: 10.1186/s12951-019-0451-9Zhao K., Zhao G.M., Wu D., Soong Y., Birk A.V., Schiller P.W., Szeto H.H. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death and reperfusion injury. J. Biol. Chem. 2004;279(33):34682– 90. DOI: 10.1074/jbc.M402999200Zhao K., Zhao G.M., Wu D., Soong Y., Birk A.V., Schiller P.W., Szeto H.H. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death and reperfusion injury. J. Biol. Chem. 2004;279(33):34682– 90. DOI: 10.1074/jbc.M402999200Birk A.V., Liu S., Soong Y., Mills W., Singh P., Warren J.D., Seshan S.V., Pardee J.D., Szeto H.H. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J. Am. Soc. Nephrol. 2013;24(8):1250–61. DOI: 10.1681/ASN.2012121216Birk A.V., Liu S., Soong Y., Mills W., Singh P., Warren J.D., Seshan S.V., Pardee J.D., Szeto H.H. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J. Am. Soc. Nephrol. 2013;24(8):1250–61. DOI: 10.1681/ASN.2012121216Yuan Y., Wang Y.Y., Liu X., Luo B., Zhang L., Zheng F., Li X.Y., Guo L.Y., Wang L., Jiang M., Pan Y.M., Yan Y.W., Yang J.Y., Chen S.Y., Wang J.N., Tang J.M. KPC1 alleviates hypoxia/reoxygenation-induced apoptosis in rat cardiomyocyte cells though BAX degradation. J. Cell Physiol. 2019;234(12):22921–22934. DOI: 10.1002/jcp.28854Yuan Y., Wang Y.Y., Liu X., Luo B., Zhang L., Zheng F., Li X.Y., Guo L.Y., Wang L., Jiang M., Pan Y.M., Yan Y.W., Yang J.Y., Chen S.Y., Wang J.N., Tang J.M. KPC1 alleviates hypoxia/reoxygenation-induced apoptosis in rat cardiomyocyte cells though BAX degradation. J. Cell Physiol. 2019;234(12):22921–22934. DOI: 10.1002/jcp.28854Ishikita A., Matoba T., Ikeda G., Koga J., Mao Y., Nakano K., Takeuchi O., Sadoshima J., Egashira K. Nanoparticle-mediated delivery of mitochondrial division inhibitor 1 to the myocardium protects the heart from ischemia-reperfusion injury through inhibition of mitochondria outer membrane permeabilization: a new therapeutic modality for acute myocardial infarction. J. Am. Heart Assoc. 2016;5(7):e003872. DOI: 10.1161/JAHA.116.003872Ishikita A., Matoba T., Ikeda G., Koga J., Mao Y., Nakano K., Takeuchi O., Sadoshima J., Egashira K. Nanoparticle-mediated delivery of mitochondrial division inhibitor 1 to the myocardium protects the heart from ischemia-reperfusion injury through inhibition of mitochondria outer membrane permeabilization: a new therapeutic modality for acute myocardial infarction. J. Am. Heart Assoc. 2016;5(7):e003872. DOI: 10.1161/JAHA.116.003872Zhou L., Zuo Z., Chow M.S. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics and clinical use. J. Clin. Pharmacol. 2005;45(12):1345–59. DOI: 10.1177/0091270005282630Zhou L., Zuo Z., Chow M.S. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics and clinical use. J. Clin. Pharmacol. 2005;45(12):1345–59. DOI: 10.1177/0091270005282630Zhang S., Li J., Hu S., Wu F., Zhang X. Triphenylphosphonium and D-α-tocopheryl polyethylene glycol 1000 succinate-modifed, tanshinone IIA-loaded lipid-polymeric nanocarriers for the targeted therapy of myocardial infarction. Int. J. Nanomedicine. 2018;13:4045–4057. DOI: 10.2147/IJN.S165590Zhang S., Li J., Hu S., Wu F., Zhang X. Triphenylphosphonium and D-α-tocopheryl polyethylene glycol 1000 succinate-modifed, tanshinone IIA-loaded lipid-polymeric nanocarriers for the targeted therapy of myocardial infarction. Int. J. Nanomedicine. 2018;13:4045–4057. DOI: 10.2147/IJN.S165590Wang J., Zhang S., Di L. Acute myocardial infarction therapy: in vitro and in vivo evaluation of atrial natriuretic peptide and triphenylphosphonium dual ligands modifi ed, baicalin-loaded nanoparticulate system. Drug. Deliv. 2021;28(1):2198–2204. DOI: 10.1080/10717544.2021.1989086.Wang J., Zhang S., Di L. Acute myocardial infarction therapy: in vitro and in vivo evaluation of atrial natriuretic peptide and triphenylphosphonium dual ligands modifi ed, baicalin-loaded nanoparticulate system. Drug. Deliv. 2021;28(1):2198–2204. DOI: 10.1080/10717544.2021.1989086.Wang X., He F., Liao Y., Song X., Zhang M., Qu L., Luo T., Zhou S., Ling Y., Guo J., Chen A. Baicalin pretreatment protects against myocardial ischemia/reperfusion injury by inhibiting mitochondrial damage-mediated apoptosis. Int. J. Cardiol. 2013;168(4):4343–5. DOI: 10.1016/j.ijcard.2013.05.077Wang X., He F., Liao Y., Song X., Zhang M., Qu L., Luo T., Zhou S., Ling Y., Guo J., Chen A. Baicalin pretreatment protects against myocardial ischemia/reperfusion injury by inhibiting mitochondrial damage-mediated apoptosis. Int. J. Cardiol. 2013;168(4):4343–5. DOI: 10.1016/j.ijcard.2013.05.077Chen Y., Jia L., Zhu G., Wang W., Geng M., Lu H., Zhang Y., Zhou M., Zhang F., Cheng X. Sortase A-mediated cyclization of novel polycyclic RGD peptides for ανβ3 integrin targeting. Bioorg. Med. Chem. Lett. 2022;73:128888. DOI: 10.1016/j.bmcl.2022.128888Chen Y., Jia L., Zhu G., Wang W., Geng M., Lu H., Zhang Y., Zhou M., Zhang F., Cheng X. Sortase A-mediated cyclization of novel polycyclic RGD peptides for ανβ3 integrin targeting. Bioorg. Med. Chem. Lett. 2022;73:128888. DOI: 10.1016/j.bmcl.2022.128888Makowski M.R., Ebersberger U., Nekolla S., Schwaiger M. In vivo molecular imaging of angiogenesis, targeting alphavbeta3 integrin expression, in a patient after acute myocardial infarction. Eur. Heart J. 2008;29(18):2201. DOI: 10.1093/eurheartj/ehn129Makowski M.R., Ebersberger U., Nekolla S., Schwaiger M. In vivo molecular imaging of angiogenesis, targeting alphavbeta3 integrin expression, in a patient after acute myocardial infarction. Eur. Heart J. 2008;29(18):2201. DOI: 10.1093/eurheartj/ehn129Yan J., Guo J., Wang Y., Xing X., Zhang X., Zhang G., Dong Z. Acute myocardial infarction therapy using calycosin and tanshinone co-loaded; mitochondrion-targeted tetrapeptide and cyclic arginyl-glycyl-aspartic acid peptide co-modifi ed lipid-polymer hybrid nano-system: preparation, characterization, and anti myocardial infarction activity assessment. Drug Deliv. 2022;29(1):2815– 2823. DOI: 10.1080/10717544.2022.2118401Yan J., Guo J., Wang Y., Xing X., Zhang X., Zhang G., Dong Z. Acute myocardial infarction therapy using calycosin and tanshinone co-loaded; mitochondrion-targeted tetrapeptide and cyclic arginyl-glycyl-aspartic acid peptide co-modifi ed lipid-polymer hybrid nano-system: preparation, characterization, and anti myocardial infarction activity assessment. Drug Deliv. 2022;29(1):2815– 2823. DOI: 10.1080/10717544.2022.2118401Fan K., Xi J., Fan L., Wang P., Zhu C., Tang Y., Xu X., Liang M., Jiang B., Yan X., Gao L. In vivo guiding nitrogen-doped carbon nanozyme for tumor catalytic therapy. Nat. Commun. 2018;9(1):1440. DOI: 10.1038/s41467-018-03903-8Fan K., Xi J., Fan L., Wang P., Zhu C., Tang Y., Xu X., Liang M., Jiang B., Yan X., Gao L. In vivo guiding nitrogen-doped carbon nanozyme for tumor catalytic therapy. Nat. Commun. 2018;9(1):1440. DOI: 10.1038/s41467-018-03903-8Singh N., Savanur M.A., Srivastava S., D'Silva P., Mugesh G. A Redox Modulatory Mn3 O4 Nanozyme with Multi-Enzyme Activity Provides Effi cient Cytoprotection to Human Cells in a Parkinson's Disease Model. Angew. Chem. Int. Ed. Engl. 2017;56(45):14267– 14271. DOI: 10.1002/anie.201708573Singh N., Savanur M.A., Srivastava S., D'Silva P., Mugesh G. A Redox Modulatory Mn3 O4 Nanozyme with Multi-Enzyme Activity Provides Effi cient Cytoprotection to Human Cells in a Parkinson's Disease Model. Angew. Chem. Int. Ed. Engl. 2017;56(45):14267– 14271. DOI: 10.1002/anie.201708573Yao J., Cheng Y., Zhou M., Zhao S., Lin S., Wang X., Wu J., Li S., Wei H. ROS scavenging Mn3O4 nanozymes for in vivo anti-in- fl ammation. Chem. Sci. 2018;9(11):2927–2933. DOI: 10.1039/c7sc05476aYao J., Cheng Y., Zhou M., Zhao S., Lin S., Wang X., Wu J., Li S., Wei H. ROS scavenging Mn3O4 nanozymes for in vivo anti-in- fl ammation. Chem. Sci. 2018;9(11):2927–2933. DOI: 10.1039/c7sc05476aZhang Y., Khalique A., Du X., Gao Z., Wu J., Zhang X., Zhang R., Sun Z., Liu Q., Xu Z., Midgley A.C., Wang L., Yan X., Zhuang J., Kong D., Huang X. Biomimetic design of mitochondria-targeted hybrid nanozymes as superoxide scavengers. Adv. Mater. 2021;33(9):e2006570. DOI: 10.1002/adma.202006570Zhang Y., Khalique A., Du X., Gao Z., Wu J., Zhang X., Zhang R., Sun Z., Liu Q., Xu Z., Midgley A.C., Wang L., Yan X., Zhuang J., Kong D., Huang X. Biomimetic design of mitochondria-targeted hybrid nanozymes as superoxide scavengers. Adv. Mater. 2021;33(9):e2006570. DOI: 10.1002/adma.202006570Huang Y., Ren J., Qu X. Nanozymes: Classifi cation, Catalytic Mechanisms, Activity Regulation and Applications. Chem. Rev. 2019;119(6):4357–4412. DOI: 10.1021/acs.chemrev.8b00672Huang Y., Ren J., Qu X. Nanozymes: Classifi cation, Catalytic Mechanisms, Activity Regulation and Applications. Chem. Rev. 2019;119(6):4357–4412. DOI: 10.1021/acs.chemrev.8b00672Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: infl uence on cardiac form and function. Physiol. Rev. 2007;87(4):1285–342. DOI: 10.1152/physrev.00012.2007Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: infl uence on cardiac form and function. Physiol. Rev. 2007;87(4):1285–342. DOI: 10.1152/physrev.00012.2007Nguyen M.M., Carlini A.S., Chien M.P., Sonnenberg S., Luo C., Braden R.L., Osborn K.G., Li Y., Gianneschi N.C., Christman K.L. Enzyme-responsive nanoparticles for targeted accumulation and prolonged retention in heart tissue after myocardial infarction. Adv. Mater. 2015; 27(37):5547–52. DOI: 10.1002/adma.201502003Nguyen M.M., Carlini A.S., Chien M.P., Sonnenberg S., Luo C., Braden R.L., Osborn K.G., Li Y., Gianneschi N.C., Christman K.L. Enzyme-responsive nanoparticles for targeted accumulation and prolonged retention in heart tissue after myocardial infarction. Adv. Mater. 2015; 27(37):5547–52. DOI: 10.1002/adma.201502003Bock-Marquette I., Saxena A., White M.D., Dimaio J.M., Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466–72. DOI: 10.1038/nature03000Bock-Marquette I., Saxena A., White M.D., Dimaio J.M., Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466–72. DOI: 10.1038/nature03000Smart N., Risebro C.A., Melville A.A., Moses K., Schwartz R.J., Chien K.R., Riley P.R. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177–82. DOI: 10.1038/nature05383Smart N., Risebro C.A., Melville A.A., Moses K., Schwartz R.J., Chien K.R., Riley P.R. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177–82. DOI: 10.1038/nature05383Huang Z., Song Y., Pang Z., Zhang B., Yang H., Shi H., Chen J., Gong H., Qian J., Ge J. Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles. Int. J. Nanomedicine. 2017;12:3023–3036. DOI: 10.2147/IJN.S131949Huang Z., Song Y., Pang Z., Zhang B., Yang H., Shi H., Chen J., Gong H., Qian J., Ge J. Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles. Int. J. Nanomedicine. 2017;12:3023–3036. DOI: 10.2147/IJN.S131949Мальчикова С.В., Трушникова Н.С., Казаковцева М.В., Максимчук-Колобова Н.С. Факторы сердечно-сосудистого риска, клинические проявления и тактика ведения инфаркта миокарда у пациентов старческого возраста и долгожителей в зависимости от гериатрического статуса. Кардиоваскулярная терапия и профилактика. 2023;22(2):3376.Malchikova S.V., Trushnikova N.S., Kazakovtseva M.V., Maksimchuk-Kolobova N.S. Cardiovascular risk factors, clinical manifestations and management of myocardial infarction in elderly and longliving patients depending on geriatric status. Cardiovascular Therapy and Prevention. 2023;22(2):3376. (In Russian). DOI: 10.15829/1728-8800-2023-3376.Shiozaki A.A., Senra T., Morikawa A.T., Deus D.F., Paladino-Filho A.T., Pinto I.M., Maranhão R.C. Treatment of patients with aortic atherosclerotic disease with paclitaxel-associated lipid nanoparticles. Clinics (Sao Paulo). 2016;71(8):435–9. DOI: 10.6061/clinics/2016(08)05Shiozaki A.A., Senra T., Morikawa A.T., Deus D.F., Paladino-Filho A.T., Pinto I.M., Maranhão R.C. Treatment of patients with aortic atherosclerotic disease with paclitaxel-associated lipid nanoparticles. Clinics (Sao Paulo). 2016;71(8):435–9. DOI: 10.6061/clinics/2016(08)05Ruiz J., Kouiavskaia D., Migliorini M., Robinson S., Saenko E.L., Gorlatova N., Li D., Lawrence D., Hyman B.T., Weisgraber K.H., Strickland D.K. The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor. J. Lipid Res. 2005;46(8):1721–31. DOI: 10.1194/jlr.M500114–JLR200Ruiz J., Kouiavskaia D., Migliorini M., Robinson S., Saenko E.L., Gorlatova N., Li D., Lawrence D., Hyman B.T., Weisgraber K.H., Strickland D.K. The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor. J. Lipid Res. 2005;46(8):1721–31. DOI: 10.1194/jlr.M500114–JLR200Maranhão R.C., Tavares E.R., Padoveze A.F., Valduga C.J., Rodrigues D.G., Pereira M.D. Paclitaxel associated with cholesterol-rich nanoemulsions promotes atherosclerosis regression in the rabbit. Atherosclerosis. 2008;197(2):959–66. DOI: 10.1016/j.atherosclerosis.2007.12.051Maranhão R.C., Tavares E.R., Padoveze A.F., Valduga C.J., Rodrigues D.G., Pereira M.D. Paclitaxel associated with cholesterol-rich nanoemulsions promotes atherosclerosis regression in the rabbit. Atherosclerosis. 2008;197(2):959–66. DOI: 10.1016/j.atherosclerosis.2007.12.051Romero M., Suárez-de-Lezo J., Herrera C., Pan M., López-Aguilera J., Suárez-de-Lezo J Jr., Baeza-Garzón F., Hidalgo-Lesmes F.J., Fer nández-López O., Martínez–Atienza J., Cebrián E., Mar tínPalanco V., Jiménez-Moreno R., Gutiérrez-Fernández R., Nogueras S., Carmona M.D., Ojeda S., Cuende N., Mata R. Randomised, double-blind, placebo-controlled clinical trial for evaluating the effi cacy of intracoronary injection of autologous bone marrow mononuclear cells in the improvement of the ventricular function in patients with idiopathic dilated myocardiopathy: a study protocol. BMC Cardiovasc. Disord. 2019;19(1):203. DOI: 10.1186/s12872–019–1182–4Romero M., Suárez-de-Lezo J., Herrera C., Pan M., López-Aguilera J., Suárez-de-Lezo J Jr., Baeza-Garzón F., Hidalgo-Lesmes F.J., Fer nández-López O., Martínez–Atienza J., Cebrián E., Mar tínPalanco V., Jiménez-Moreno R., Gutiérrez-Fernández R., Nogueras S., Carmona M.D., Ojeda S., Cuende N., Mata R. Randomised, double-blind, placebo-controlled clinical trial for evaluating the effi cacy of intracoronary injection of autologous bone marrow mononuclear cells in the improvement of the ventricular function in patients with idiopathic dilated myocardiopathy: a study protocol. BMC Cardiovasc. Disord. 2019;19(1):203. DOI: 10.1186/s12872–019–1182–4Attar A., Nouri F., Yazdanshenas A., Hessami K., Vosough M., Abdi-Ardekani A., Izadpanah P., Ramzi M., Kojouri J., Pouladfar G., Monabati A. Single vs. double intracoronary injection of mesenchymal stromal cell after acute myocardial infarction: the study protocol from a randomized clinical trial: BOOSTER–TAHA7 trial. Trials. 2022;23(1):293. DOI: 10.1186/s13063-022-06276-yAttar A., Nouri F., Yazdanshenas A., Hessami K., Vosough M., Abdi-Ardekani A., Izadpanah P., Ramzi M., Kojouri J., Pouladfar G., Monabati A. Single vs. double intracoronary injection of mesenchymal stromal cell after acute myocardial infarction: the study protocol from a randomized clinical trial: BOOSTER–TAHA7 trial. Trials. 2022;23(1):293. DOI: 10.1186/s13063-022-06276-yOommen S., Cantero Peral S., Qureshi M.Y., Holst K.A., Burkhart H.M., Hathcock M.A., Kremers W.K., Brandt E.B., Larsen B.T., Dearani J.A., Edwards B.S., Maleszewski J.J., Nelson T.J. Wanek Program Pre-Clinical Pipeline. Autologous Umbilical Cord Blood-Derived Mononuclear Cell Therapy Promotes Cardiac Proliferation and Adaptation in a Porcine Model of Right Ventricle Pressure Overload. Cell Transplant. 2022;31:9636897221120434. DOI: 10.1177/09636897221120434Oommen S., Cantero Peral S., Qureshi M.Y., Holst K.A., Burkhart H.M., Hathcock M.A., Kremers W.K., Brandt E.B., Larsen B.T., Dearani J.A., Edwards B.S., Maleszewski J.J., Nelson T.J. Wanek Program Pre-Clinical Pipeline. Autologous Umbilical Cord Blood-Derived Mononuclear Cell Therapy Promotes Cardiac Proliferation and Adaptation in a Porcine Model of Right Ventricle Pressure Overload. Cell Transplant. 2022;31:9636897221120434. DOI: 10.1177/09636897221120434Assuncao-Jr A.N., Rochitte C.E., Kwong R.Y., Wolff-Gowdak L.H., Krieger J.E., Jerosch-Herold M. Bone marrow cells improve coronary fl ow reserve in ischemic nonrevascularized myocardium: a MiHeart/IHD quantitative perfusion CMR substudy. JACC Cardiovasc. Imaging. 2022;15(5):812–824. DOI: 10.1016/j.jcmg.2021.12.011Assuncao-Jr A.N., Rochitte C.E., Kwong R.Y., Wolff-Gowdak L.H., Krieger J.E., Jerosch-Herold M. Bone marrow cells improve coronary fl ow reserve in ischemic nonrevascularized myocardium: a MiHeart/IHD quantitative perfusion CMR substudy. JACC Cardiovasc. Imaging. 2022;15(5):812–824. DOI: 10.1016/j.jcmg.2021.12.011Kharlamov A.N., Tyurnina A.E., Veselova V.S., Kovtun O.P., Shur V.Y., Gabinsky J.L. Silica-gold nanoparticles for atheroprotective management of plaques: results of the NANOM-FIM trial. Nanoscale. 2015;7(17):8003–15. DOI: 10.1039/c5nr01050kKharlamov A.N., Tyurnina A.E., Veselova V.S., Kovtun O.P., Shur V.Y., Gabinsky J.L. Silica-gold nanoparticles for atheroprotective management of plaques: results of the NANOM-FIM trial. Nanoscale. 2015;7(17):8003–15. DOI: 10.1039/c5nr01050k

The authors declare that there are no conflicts of interest present.